Oncolytics Biotech Inc. (T:ONC*CA)
Business Focus: Biotechnology & Medical Research (NEC)
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| Company Contact | |
| Address: | 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7 CALGARY AB T2R 0C5 |
| Tel: | N/A |
| Website: | https://www.oncolyticsbiotech.com |
| IR: | See website |
| Key People | ||
| Matthew C. Coffey President, Chief Executive Officer, Director | Kirk J. Look Chief Financial Officer | Andrew De Guttadauro Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. |
| Allison Hagerman Vice President - Product Development | Thomas C. Heineman Chief Medical Officer of Oncolytics Biotech (U.S.) | |
| Business Overview |
| Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company's primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Oncolytics Biotech Inc revenues was not reported. Net loss increased 12% to C$27.8M. Higher net loss reflects Foreign exchange (loss) gain decrease from C$1.7M (income) to C$475K (expense), Research and development - Balancing val increase of 25% to C$10.1M (expense), Employee compensation and benefits increase of 16% to C$3.3M (expense). |
| Employees: | 29 as of Dec 31, 2022 |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $76.38M as of Dec 31, 2023 |
| Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
| EBITDA (TTM): | -$33.39M as of Dec 31, 2023 |
| Net annual income (TTM): | -$27.75M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$28.46M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 75,419,768 as of Mar 26, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.